Doximity, Inc. Class A DOCS

A number of stocks jumped in the afternoon session after the Bureau of Economic Analysis reported a 0.9% increase in personal consumption expenditures for August, signaling resilient consumer demand alongside steady economic expansion.

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Doximity recently launched Bedside Bench, an open-source benchmark designed to evaluate clinical-grade AI using realistic bedside scenarios, and independent testing by Fireworks ranked its Doximity Ask system ahead of several frontier models. This move highlights how domain-specific, healthcare-focused AI can outperform general-purpose systems on clinically relevant tasks, potentially strengthening Doximity’s positioning as a trusted tool for physicians. We’ll now examine how Doximity’s...

SAN FRANCISCO, September 22, 2026--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform.

Paul Jorgensen has been ordered to pay the sum in the wake of allegations of insider trading.

Outcomes4Me Inc., the leading direct-to-patient health technology company leveraging AI to revolutionize cancer care, announced today that Jim Longley, most recently the Senior Vice President: AI Partnerships at OpenEvidence, has joined Outcomes4Me as Chief Revenue Officer. With more than two decades of senior leadership experience across healthcare technology, commercial strategy, and business development, Jim will lead Outcomes4Me's revenue organization as the company enters its next exciting

Since March 2026, Doximity has been in a holding pattern, posting a small return of 2.8% while floating around $26.41. The stock also fell short of the S&P 500’s 12.1% gain during that period.

A number of stocks jumped in the afternoon session after quarterly earnings and upbeat corporate commentary signaled that artificial intelligence is driving growth across enterprise software rather than threatening legacy business models.

Software is eating the world, and virtually no business is left untouched by it. Companies bringing it to life have been rewarded with explosive earnings growth, and the upward trend shows no signs of stopping as the industry has posted a 44.6% gain over the past six months, beating the S&P 500 by 32.9 percentage points.

SAN FRANCISCO, August 25, 2026--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don't.

Doximity stock has had a difficult five year stretch, with shareholders seeing the share price decline 71.8%, even as recent AI driven products have drawn fresh attention. At the current price near US$24.94, the key issue is whether the latest enthusiasm lines up with what the intrinsic value and market based checks say about Doximity. Over five years, the share price decline of 71.8% points to investors reassessing what they are willing to pay for Doximity. Growth expectations around...

Doximity (DOCS) is back in focus after its latest quarterly report showed higher sales, raised full year revenue guidance, and continued margin pressure tied to heavier spending on AI tools. See our latest analysis for Doximity. At a share price of US$24.94, Doximity has seen a 30 day share price return of 15.89% and a 90 day share price return of 25.58%. However, the year to date share price return is down 42.39% and the 1 year total shareholder return is down 60.79%. This points to...